Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 06, 2023

Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and von Hippel–Lindau Disease–Associated Tumors

Medical Sciences (Basel, Switzerland)

 

Additional Info

Medical Sciences (Basel, Switzerland)
Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors
Med Sci (Basel) 2023 Jun 30;[EPub Ahead of Print], C Suárez, M Vieito, A Valdivia, M González, J Carles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading